There are no significant differences in outcomes post-AMI in patients with systemic lupus erythematosus vs the general population.

The Global Systemic Lupus Erythematosus Treatment Market is valued approximately at USD 2.95 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 8.64% over the forecast ...

Current treatment options for systemic lupus erythematosus (SLE) consists of glucocorticoids, antimalarials, immunosuppressives, and a few biologics, approved or of 'off-label'. Through judicious ...

Immune cells called monocytes produce a key inflammatory protein called interleukin-1 beta (IL-1β) through an unconventional ...

Adult patients hospitalized for aseptic or septic revision TKA were eligible for inclusion. Patients with SLE were propensity score matched in a 1:4 ratio with individuals without the disease. The ...

SLE: Systemic lupus erythematosus. Symptoms of systemic lupus erythematosus (SLE) must be brought under control to avert immediate consequences and afford the patient a better quality of life.

Neuropsychiatric systemic lupus erythematosus (NPSLE), or central nervous system lupus, can be challenging to diagnose ...

Clinical stage biopharma Kezar Life Sciences is discontinuing its lupus nephritis (LN) clinical programme following the death ...

Systemic lupus can be mild or severe. Cutaneous lupus erythematosus This form of lupus is limited to the skin and can cause many types of rashes and lesions. Drug-induced lupus erythematosus This is a ...

Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...

The following is a summary of “Coronary Artery Calcification Progression in Patients With Systemic Lupus Erythematosus,” ...